Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7304202 | 0.85 | ALDH1A1 (0.59) | CAPN1LMNAALDH1A1USP2HPGD | |
| SCHEMBL7303296 | 0.85 | ALDH1A1 (0.59) | CAPN1LMNAALDH1A1USP2HPGD | |
| SCHEMBL13917842 | 0.80 | NPC1 (0.59) | LMNAPSMB5ALDH1A1USP30TDP1 | |
| SCHEMBL4889588 | 0.80 | LMNA (0.71) | LMNAPSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL9716670 | 0.80 | LMNA (0.71) | LMNAPSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL7778087 | 0.80 | LMNA (0.71) | LMNAPSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL16452917 | 0.80 | LMNA (0.71) | LMNAPSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL7940901 | 0.80 | PSMB5 (0.53) | LMNAPSMB5MEN1KMT2AALDH1A1 | |
| SCHEMBL16565957 | 0.79 | CTSC (0.65) | CAPN1CYP2C19 | |
| SCHEMBL7297841 | 0.79 | L3MBTL1 (0.61) | CAPN1LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | claimed |
| EP-0696208-B1 | ORAL DRUG DELIVERY COMPOSITIONS | EMISPHERE TECH INC (US) | 2001-08-22 | — | — | EP | claimed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | claimed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998025589-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714167-A | REVERSIBLY FORMING SUPRAMOLECULAR COMPLEX OF ACTIVE AGENT WITH PERTURBANT; DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | PTMS, ADM2, DNPEP | CAPN1 2406/4885LMNA 3398/4885PSMB5 972/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | CAPN1 1942/4885LMNA 2828/4885PSMB5 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.